share_log

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo在肝臟大會上重點介紹了FXR314在MASH的2期結果,顯示與其他FXR激動劑相比,具有顯著的降低肝脂和改善安全性的優勢
Benzinga ·  2024/11/20 21:08

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo在肝臟大會上重點介紹了FXR314在MASH的2期結果,顯示與其他FXR激動劑相比,具有顯著的降低肝脂和改善安全性的優勢

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論